Inherited dementias

Neurologic Clinics

Volumn 20, Issue 3, 2002, Pages 779-808

  Hedera, Peter ^a   Turner, R Scott ^b,c  

^a VANDERBILT UNIVERSITY   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^c VA ANN ARBOR HEALTHCARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALZHEIMER DISEASE; AUTOSOMAL DOMINANT INHERITANCE; DEMENTIA; FAMILIAL DISEASE; FRONTOTEMPORAL DEMENTIA; GENE MUTATION; GENETIC DISORDER; GENETIC RISK; HUMAN; LEUKOENCEPHALOPATHY; PRION DISEASE; PRIORITY JOURNAL; PROTEIN DOMAIN; REVIEW; VASCULAR AMYLOIDOSIS;

ALZHEIMER DISEASE; CEREBRAL AMYLOID ANGIOPATHY; DEMENTIA; DEMENTIA, MULTI-INFARCT; DNA MUTATIONAL ANALYSIS; GENETIC MARKERS; GENETIC SCREENING; MOLECULAR DIAGNOSTIC TECHNIQUES; PRION DISEASES;

EID: 0036699577     PISSN: 07338619     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0733-8619(01)00020-2     Document Type: Review

References (112)

1. Alzheimer A. Über eine eigenartige Erkrankung der Hirnrinde. Allg Z Psychiatr 1907;64:146-8.
2. Alzheimer A. Uber eigenartige Krankheitsfalle des spateren Alters. Zeitchrift fur die Gesamte Neurologie und Psychiatrie 1911;4:356-8.
3. Artavanis-Tsakonas S, Rand MD, Lake RJ. Notch signaling: cell fate control and signal integration in development. Science 1999;284:770-6.
4. Baudrimont M, Dubas F, Joutel A, Tournier-Lasserve E, Bousser M-G. Autosomal dominant leukoencephalopathy and subcortical ischemic stroke. A clinicopathological study. Stroke 1993;24:122-5.
5. Braak H, Braak E. Neuropathologic staging of Alzheimer related changes. Acta Neuropathol 1991;82:239-59.
6. Brown P, Cathala F, Castaigne P, Gajdusek DC. Creutzfeldt-Jakob disease: clinical analysis of a consecutive series of 230 neuropathologically verified cases. Ann Neurol 1986;20:597-602.
7. Brown P, Goldfarb LG, Kovanen J, et al. Phenotypic characteristics of familial Creutzfeldt-Jakob disease associated with the codon 178-asn PRNP mutation. Ann Neurol 1992;31:282-5.
8. Brown J, Ashworth A, Gydesen S, et al. Familial non-specific dementia maps to chromosome 3. Hum Mol Genet 1995;4:1625-8.
9. Budka H, Aguzzi A, Brown P, et al. Neuropathological diagnostic criteria for Creutzfeldt-Jakob disease (CJD) and other human spongiform encephalopathies (prion disease). Brain Pathol 1995;5:459-66.
10. Buee L, Bussiere T, Buee-Scherrer V, Delacourte A, Hof PR. Tau protein isoforms, phosphorylation and role in neurodegenerative disorders. Brain Res Rev 2000;33:95-130.
11. Bueler H, Fischer M, Lang Y, et al. Normal development and behaviour of mice lacking the neuronal cell-surface PrP protein. Nature 1992;356:577-82.
12. Bueuler H, Aguzzi A, Sailer A, et al. Mice devoid of PrP are resistant to scrapie. Cell 1993;73:1339-47.
13. Cherny RA, Atwood CS, Xilinas ME, et al. Treatment with a copper-zinc chelator markedly and rapidly inhibits β-amyloid accumulation in Alzheimer's disease transgenic mice. Neuron 2001;30:665-76.
14. Chow TW, Miller BL, Hayashi VN, Geschwind DH. Inheritance of frontotemporal dementia. Arch Neurol 1999;56:817-22.
15. Collinge J. Prion diseases of humans and animals: Their causes and molecular basis. Annu Rev Neurosci 2001;24:519-50.
16. Conrad C, Andreanis A, Trojanowski JQ, et al. Genetic evidence for the involvement of tau in progressive supranuclear palsy. Ann Neurol 1997;41:277-81.
17. Davies P, Maloney AJF. Selective loss of central cholinergic neurons in Alzheimer's disease. Lancet 1976;2:1403.
18. Davous P. CADASIL: a review with proposed diagnostic criteria. Eur J Neurol 1998;5:219-33.
19. Desmond DW, Moroney JT, Lynch T, et al. The natural history of CADASIL. A pooled analysis of previously published cases. Stroke 1999;30:1230-3.
20. Diagnostic and Statistical Manual of Mental Disorders. (4th ed): American Psychiatric Association, Washington, D.C., 1994.
21. Dichgans M, Mayer M, Uttner I, et al. The phenotypic spectrum of CADASIL: Clinical findings in 102 cases. Ann Neurol 1998;44:731-9.
22. Doh-ura K, Tateishi J, Sasaki H, Kitamoto T, Sakaki Y. Pro-to-leu change at position 102 of prion protein is the most common but not the sole mutation related to Gerstmann-Straussler syndrome. Biochem Biophys Res Commun 1989;163:974-9.
23. Doody RS, Stevens JC, Beck C, et al. Practice parameter: Management of dementia (an evidence-based review). Neurology 2001;56:1154-66.
24. Evans DA, Funkenstein HH, Albert MS, et al. Prevalence of Alzheimer's disease in a community population of older persons higher than previously reported. JAMA 1989;262:2551-6.
25. Evenhuis HM. The natural history of dementia in Down's syndrome. Arch Neurol 1990;47:263-7.
26. Foster NL, Wilhelmsen KC, Sima AAF, et al. Frontotemporal dementia and parkinsonism linked to chromosome 17: A consensus conference. Ann Neurol 1997;41:706-15.
27. Fukutake T, Hirayama K. Familial young-adult onset arteriosclerotic leukoencephalopathy with alopecia and lumbago without arterial hypertension. Eur Neurol 1995;35:69-79.
28. Gajdusek DC, Gibbs CJJ, Alpers MP. Experimental transmission of a kuru-like syndrome to chimpanzee. Nature 1966;209:794-6.
29. Games D, Adams D, Alessandrini R, et al. Alzheimer-type neuropathology in transgenic mice expressing V717F β-amyloid precursor protein. Nature 1995;373:523-7.
30. Gau J-T, Steinhilb ML, Kao T-C, et al. Stable β-secretase activity and presynaptic cholinergic function during progressive CNS amyloidogenesis in Tg2576 mice. Am J Pathol 2002;160:731-8.
31. Gearing M, Mirra SS, Hedreen JC, et al. The Consortium to Establish Registry for Alzheimer's Disease (CERAD) Part X. Neuropathologic confirmation of the clinical diagnosis of Alzheimer's disease. Neurology 1995;45:461-6.
32. Goedert M, Spillanti MG, Jakes R, Rutherford D, Crowther RA. Multiple isoforms of human microtubule-associated protein tau: sequence and localization in neurofibrillary tangles of Alzheimer's disease. Neuron 1989;3:519-26.
33. Goldfarb LG, Brown P, McCombie WR, et al. Transmissible familial Creutzfeldt-Jakob disease associated with five, seven, and eight extra octapeptide coding repeats in the PRNP gene. Proc Nat Acad Sci 1991;88:10926-30.
34. LYS mutation: an analysis of 45 families. Eur J Epidemiol 1991;7:477-86.
35. Goldfarb LG, Brown P, Haltia M, et al. Creutzfeldt-Jakob disease cosegregates with the codon 178-asn PRNP mutation in families of European origin. Ann Neurol 1992;31:274-81.
36. Goldfarb LG, Petersen RB, Tabaton M, et al. Fatal familial insomnia and familial Creutzfeldt-Jakob disease: disease phenotype determined by a DNA polymorphism. Science 1992;258:806-8.
37. Gotz J, Chen F, van Dorpe J, Nitsch RM. Formation of neurofibrillary tangles in P301L tau transgenic mice induced by Aβ42 fibrils. Science 2001;293:1491-5.
38. Gustafson L. Frontal lobe degeneration of non-Alzheimer type. Clinical picture and differential diagnosis. Arch Gerontol Geriatr 1987;6:209-23.
39. Haass C, Steiner H. Protofibrils, the unifying toxic molecule of neurodegenerative disorders? Nat Neurosci 2001;4:859-60.
40. Hedera P, Friedland RP. Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy: Study of two American families with predominant dementia. J Neurol Sci 1997;146:27-33.
41. Hong M, Zhukareva V, Vogelsberg-Ragaglia V, et al. Mutation-specific functional impairments in distinct tau isoforms of hereditary FTDP-17. Science 1998;282:1914-7.
42. Hsiao K, Baker HF, Crow TJ, et al. Linkage of a prion protein missense variant to Gerstmann-Straussler syndrome. Nature 1989;338:342-5.
43. Hsiao K, Meiner Z, Kahana E, et al. Mutation of the prion protein in Libyan Jews with Creutzfeldt-Jakob disease. N Engl J Med 1991;324:1091-7.
44. Hsiao K, Dlouhy SR, Farlow MR, et al. Mutant prion proteins in Gerstmann-Straussler-Scheinker disease with neurofibrillary tangles. Nat Genet 1992;1:68-71.
45. Hsiao K, Chapman P, Nilsen S, et al. Correlative memory deficits, Aβ elevation and amyloid plaques in transgenic mice. Science 1996;274:99-102.
46. Hsich G, Kenny K, Gibbs Jr. CJ. The 14-3-3 brain protein in the cerebrospinal fluid as a marker for transmissible spongiform encephalopathies. N Engl J Med 1996;335:924-30.
47. Hutton M, Lendon CL, Rizzu P, et al. Association of missense and 5′-splice site mutations in tau with the inherited dementia FTDP-17. Nature 1998;393:702-5.
48. Johnson RT, Gibbs Jr. CJ. Creutzfeldt-Jakob disease and related transmissible spongiform encephalopathies. N Engl J Med 1998;339:1994-2003.
49. Joutel A, Corpechot C, Ducros A, et al. Notch-3 mutations in CADASIL, a hereditary condition causing stroke and dementia. Nature 1996;383:707-10.
50. Joutel A, Vahedi K, Corpechot C, et al. Strong clustering and stereotypic nature of Notch-3 mutations in CADASIL patients. Lancet 1997;350:1511-5.
51. Joutel A, Andreux F, Gaulis S, et al. The ectodomain of the Notch3 receptor accumulates within the cerebrovasculature of CADASIL patients. J Clin Invest 2000;105:597-605.
52. Khachaturian ZS. Diagnosis of Alzheimer's disease. Arch Neurol 1985;42:1097-105.
53. Knapp MJ, Knopman DS, Solomon PR, et al. A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer's disease. JAMA 1994;271:985-91.
54. Knopman DS, DeKosky ST, Cummings JL, et al. Practice parameter: Diagnosis of dementia (an evidence-based review). Neurology 2001;56:1143-53.
55. Kosunen O, Soininen H, Paljarvi L, et al. Diagnostic accuracy of Alzheimer's disease: a neuropathological study. Acta neuropathol 1996;91:185-93.
56. Kukull WA, Ganguli M. Epidemiology of dementia: concepts and overview. Neurol Clin 2000;18:923-50.
57. Lee VM-Y, Trojanowski JQ. Transgenic mouse model of tauopathies: Prospects for animal models of Pick's disease. Neurology 2001;56(Suppl 4):S26-30.
58. Lendon CL, Lynch T, Norton J, et al. Hereditary dysphasic disinhibition dementia. A frontotemporal dementia linked to 17q21-22. Neurology 1998;50:1546-55.
59. Lesnik Oberstein SAJ, van den Boom R, van Buchem MA, et al. Cerebral microbleeds in CADASIL. Neurology 2001;57:1066-70.
60. Lewis J, Dickson DW, Lin W-L, et al. Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP. Science 2001;293:187-491.
61. Mas JL, Dilouya A, de Recondo J. A familial disorder with subcortical strokes, dementia, and leukoencephalopathy. Neurology 1992;42:1015-20.
62. Mayer M, Straube A, Bruening R, et al. Muscle and skin biopsies are a sensitive diagnostic tool in the diagnosis of CADASIL. J Neurol 1999;246:526-32.
63. Mayeux R, Sano M. Treatment of Alzheimer's Disease. N Engl J Med 1999;341:1670-9.
64. McKhann G, Drachman D, Folstein M, et al. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984;34:939-44.
65. McKhann GM, Albert MS, Grossman M, Miller B, Dickson D, Trojanowski JQ. Clinical and pathological diagnosis of frontotemporal dementia. Report of the work group on frontotemporal dementia and Pick's disease. Arch Neurol 2001;58:1803-9.
66. Medori R, Tritschler HJ, LeBlanc A, et al. Fatal familial insomnia, a prion disease with a mutation at codon 178 of the prion protein gene. N Engl J Med 1992;326:444-9.
67. Mesulam M-M. Slowly progressive aphasia without generalized dementia. Ann Neurol 1982;11:592-8.
68. Mirra SS, Heyman A, McKeel D, et al. The consortium to establish a registry for Alzheimer's disease (CERAD): Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology 1991;41:479-86.
69. Neary D, Snowden JS, Gustafson L, et al. Frontotemporal lobar degeneration. A consensus on clinical diagnostic criteria. Neurology 1998;51:1546-54.
70. O'Sullivan M, Jarosz JM, Martin RJ, et al. MRI hyperintensities of the temporal lobe and external capsule in patients with CADASIL. Neurology 2001;56:628-34.
71. Owen F, Poulter M, Lofthouse R, et al. Insertion in prion protein gene in familial Creutzfeldt-Jakob disease. Lancet 1989;1:51-2.
72. Owen F, Poulter M, Collinge J, Crow TJ. Codon 129 changes in the prion protein gene in Caucasians. Am J Hum Genet 1990;46:1215-6.
73. Petersen RC, Stevens JC, Ganguli M, et al. Practice parameter: Early detection of dementia: Mild cognitive impairment (an evidence-based review). Neurology 2001;56:1133-42.
74. Pick A. Uber die Beziehungen der senilen Hirnatrophie zur Aphasie. Prager Medizinische Wochenschrift 1892;17:165-7.
75. Plant GT, Revesz T, Barnard RO, Harding AE, Gautier-Smith PC. Familial cerebral amyloid angiopathy with nonneuritic amyloid plaque formation. Brain 1990;113:721-47.
76. Poorkaj P, Bird T, Wijsman E, et al. Tau is a candidate gene for chromosome 17 frontotemporal dementia. Ann Neurol 1998;43:815-25.
77. Poorkaj P, Tsuang D, Wijsman E, et al. TAU is a susceptibility gene for amyotrophic lateral sclerosis-parkinsonism-dementia complex of Guam. Arch Neurol 2001;58:1871-8.
78. Prusiner SB. Novel proteinaceous infectious particles cause scrapie. Science 1982;216:136-144.
79. Prusiner SB. Molecular biology of prion diseases. Science 1991;252:1515-22.
80. Riley DE, Lang AE, Lewis A, et al. Cortical-basal ganglionic degeneration. Neurology 1990;40:1203-12.
81. Robakis NK, Devine Gage EA, Jenkins EC, et al. Localization of a human gene homologous to the PrP gene on a short arm of chromosome 20 and detection of PrP-related antigens in normal human brain. Biochem Biophys Res Commun 1986;140:758-65.
82. Rogers SL, Friedhoff LT. The efficacy and safety of donepezil in patients with Alzheimer's disease: results of a US Multicentre, Randomized, Double-Blind, Placebo-Controlled Trial. The Donepezil Study Group. Dementia 1996;7:293-303.
83. Rossor MN. Pick's disease. A clinical overview. Neurology 2001;56(Suppl 4):S3-5.
84. Sano M, Ernesto C, Thomas RG, et al. A controlled trial of selegiline, α-tocopherol, or both as treatments for Alzheimer's disease. The Alzheimer's Disease Cooperative Study. N Engl J Med 1997;336:1216-22.
85. Schenk D, Barbour R, Dunn W, et al. Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 1999;400:173-7.
86. Scheuner D, Eckman C, Jensen M, et al. Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease. Nat Med 1996;2:864-70.
87. Selkoe DJ. Alzheimer's disease: genes, proteins, and therapy. Physiol Rev 2001;81:741-66.
88. Sergeant N, Wattez A, Delacourte A. Neurofibrillary degeneration in progressive supranuclear palsy and corticobasal degeneration: tau pathologies with exclusively 'exon 10' isoforms. J Neurochem 1999;72:1243-9.
89. Snowden JS, Goulding PJ, Neary D. Semantic dementia: a form of circumscribed atrophy. Behav Neurol 1989;2:167-82.
90. Sonninem V, Savontaus M-L. Hereditary multi-infarct dementia. Eur Neurol 1987;27:209-15.
91. Sourander P. Walinder. Hereditary multi-infarct dementia. Morphological and clinical studies of a new disease. Acta Neuropathol 1977;39:247-54.
92. Spillanti MG, Murrell JR, Goedert M, et al. Mutation in the tau gene in familial multiple system tauopathy with presenile dementia. Proc Natl Acad Sci USA 1998;96:7737-41.
93. Stevens M, van Duijn CM, Kamphorts W, et al. Familial aggregation in frontotemporal dementia. Neurology 1998;50:1541-5.
94. Strittmatter WJ, Saunders AM, Schmechel D, et al. Apoliproprotein E - high avidity binding to β-amyloid and increased frequency of type-4 allele in late-onset Alzheimer's disease. Proc Natl Acad Sci USA 1994;90:1977-81.
95. Stromgrem E, Dalby A, Dalby MA, Ranheim B. Cataracts, deafness, cerebellar ataxia, psychosis, and dementia - a new syndrome. Acta Neurol Scand 1970;46(suppl.43):261-2.
96. Tang MX, Jacobs D, Stern Y, et al. Effect of oestrogen during menopause on risk and age at onset of Alzheimer's disease. Lancet 1996;348:429-32.
97. The Lund and Manchester Groups. Clinical and neuropathological criteria for frontotemporal dementia. J Neurol Neurosurg Psychiat 1994;57:416-8.
98. The National Institute on Aging and Reagan Institute Working Group on Diagnostic Criteria for the Neuropathologic Assessment of Alzheimer's Disease. Consensus recommendations for the postmortem diagnosis of Alzheimer's disease. Neurobiol Aging 1997;18:S1-2.
99. The Ronald and Nancy Reagan Research Institute of the Alzheimer's Association and the National Institute on Aging Working Group. Consensus report of the Working Group on: Molecular and biochemical markers of Alzheimer's disease. Neurobiol Aging 1998;19:109-16.
100. Tournier-Lasserve E, Iba-Zizen M-T, Romero N, Bousser M-G. Autosomal dominant syndrome with stroke-like episodes and leukoencephalopathy. Stroke 1991;22:1297-302.
101. Tournier-Lasserve E, Joutel A, Melki J, et al. Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy maps to chromosome 19q12. Nat Genet 1993;3:256-9.
102. Turner RS, Kenyon LC, Trojanowski JQ, Gonatas N, Grossman M. Clinical, neuroimaging, and pathologic features of progressive non-fluent aphasia. Ann Neurol 1996;39:166-73.
103. Turner RS. Alzheimer's disease in man and transgenic mice. Females at higher risk. Am J Pathol 2001;158:797-801.
104. Vidal R, Frangione B, Rostagno A, et al. A stop-codon mutation in the BRI gene associated with familial British dementia. Nature 1999;399:776-81.
105. Vidal R, Revesz T, Rostagno A, et al. A decamer duplication in the 3-prime region of the BRI gene originates an amyloid peptide that is associated with dementia in a Danish kindred. Proc Nat Acad Sci 2000;97:4920-5.
106. Wijker M, Wszolek ZK, Wolters ECH, et al. Localization of the gene for rapidly pro-gressive autosomal dominant parkinsonism and dementia with pallido-ponto-nigral degeneration to chromosome 17q21. Hum Mol Genet 1996;5:151-4.
107. Wilhelmsen KC, Lynch T, Pavlov E, Higgins M, Hygaard TG. Localization of disinhibition-dementia-parkinsonism-amyotrophy complex to 17q21-22. Am J Hum Genet 1994;55:1159-65.
108. Will RG, Matthews WB. A retrospective study of Creutzfeldt-Jakob disease in England and Wales 1970-79. I: Clinical features. J Neurol Neurosurg Psych 1984;47:134-140.
109. Will RG, Zeidler M, Stewart GE, et al. Diagnosis of new variant Creutzfeldt-Jakob disease. Ann Neurol 2000;47:575-82.
110. Worster-Drought C, Hill TR, McMenemey WH. Familial presenile dementia with spastic paralysis. Brain 1933;14:27-34.
111. Yebenes de JG, Sarasa JL, Daniel SE, Lees AJ. Familial progressive supranuclear palsy. Description of a pedigree and review of the literature. Brain 1995;118:1095-103.
112. Chabriat H, Vahedi K, Iba-Zizen MT, et al. Clinical spectrum of CADASIL: a study of 7 families. Lancet 1995;346:934-9.